Key Highlights

  • The third-quarter 2026 net loss for Compass Pathways (NASDAQ:CMPS) was USD 9.8 million as of November 3, 2026, cushioned by a USD 40.8 million non-cash gain tied to Warrant liabilities.
  • Cash and equivalents climbed to USD 444.0 million at September 30, 2026 from USD 149.6 million at December 31, 2025, and management expects that balance to support operations into 2028.
  • The COMP360 rolling new drug application for treatment-resistant depression is close to finished, with the final portion expected within two weeks and a first-half 2027 launch targeted, contingent on approval.
  • Research and development spending came to USD 23.5 million in the quarter and selling, general and administrative expense to USD 33.0 million, largely from preparations for a commercial launch.

Warrant Accounting Gain Trims the Reported Loss

Compass Pathways (NASDAQ:CMPS) reported third-quarter 2026 results on November 3, 2026. The loss was USD 9.8 million, or USD 0.07 per basic share and USD 0.31 per diluted share, though a USD 40.8 million non-cash gain on warrant liabilities accounts for most of the narrowing. Research and Development and selling, general and administrative costs together totaled USD 56.5 million, by simple arithmetic on the two reported lines. Over nine months the loss reached USD 172.4 million, or USD 1.35 per share. The London-based developer is advancing COMP360, a psilocybin therapy for treatment-resistant depression and post-traumatic stress disorder. Because the gain is non-cash and linked to warrant valuations, it does not show lower underlying spending.

Filing Timeline, Priority Voucher and a 2027 Launch Window

The rolling application for COMP360 is being submitted in pieces, and the company expects to file the last portion within two weeks. No acceptance or action date has been announced. The company also said a National Priority Voucher could compress review to one to two months, though any launch in the first half of 2027 depends on approval by the US Food and Drug Administration. Separately, 52-week open-label data from the COMP005 study showed added benefit from an extra 25 mg dose and durability out to one year.

Screen EPS Growth Versus a Warrant-Driven Result

Published market data lists a one-year EPS change of 109.03% and a price near USD 8.36, down 2.68%, yet neither figure could be matched to the filing and the screen date is unconfirmed. Because the company loses money, shifts in loss per share mostly reflect warrant swings, a non-operating item, rather than operating improvement. Debt rose to USD 51.0 million from USD 31.6 million at year-end 2025. Regulatory delay, launch costs and possible dilution from further financing remain risks, and cash funding into 2028 depends on the pace of spending. Approval, if it arrives, would bring commercial costs that the current selling expense line only hints at.

Where Things Stand

Mostly accounting rather than lower spending. The USD 9.8 million loss at Compass Pathways (NASDAQ:CMPS) was narrow because warrant liabilities fell in value by USD 40.8 million, while operating costs rose with launch preparation. The Balance Sheet looks strong with USD 444.0 million of cash and funding expected into 2028. The next dated event is the final submission, expected within about two weeks of the November 3, 2026 release, followed by any agency word on timing. A first-half 2027 launch stays conditional on approval. Shareholders following the name should also track how far the warrant line swings in future quarters.